Header Logo

Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor.

Mathew Thomas V, Bindal P, Ann Alexander S, McDonald K. Nivolumab-induced hepatitis: A rare side effect of an immune check point inhibitor. J Oncol Pharm Pract. 2020 Mar; 26(2):459-461.

View in: PubMed